Biologics in rheumatoid arthritis: a lifetime treatment or possibility of drug holidays?

Affiliations

Comment

Bruno Fautrel. Nat Rev Rheumatol. 2023 Oct.

. 2023 Oct;19(10):611-612.

doi: 10.1038/s41584-023-01005-4.

¹ Department of Rheumatology, Sorbonne University AP-HP, Paris, France. bruno.fautrel@aphp.fr.

No abstract available

Comment on

Factors associated with discontinuation of biologics in patients with inflammatory arthritis in remission: data from the BIOBADASER registry.
Valero M, Sánchez-Piedra C, Freire M, Colazo M, Busquets N, Meriño-Ibarra E, Rodríguez-Lozano C, Manrique S, Campos C, Sánchez-Alonso F, Castrejón I. Valero M, et al. Arthritis Res Ther. 2023 May 22;25(1):86. doi: 10.1186/s13075-023-03045-3. Arthritis Res Ther. 2023. PMID: 37217997 Free PMC article.

1. Smolen, J. S. et al. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2022 update. Ann. Rheum. Dis. 82, 3–18 (2023). - DOI - PubMed
1. Aga, A. B. et al. Time trends in disease activity, response and remission rates in rheumatoid arthritis during the past decade: results from the NOR-DMARD study 2000–2010. Ann. Rheum. Dis. 74, 381–388 (2015). - DOI - PubMed
1. Combe, B. et al. Current favourable 10-year outcome of patients with early rheumatoid arthritis: data from the ESPOIR cohort. Rheumatology (Oxford) 60, 5073–5079 (2021). - DOI - PubMed
1. Fautrel, B. & Den Broeder, A. A. De-intensifying treatment in established rheumatoid arthritis (RA): Why, how, when and in whom can DMARDs be tapered? Best Pract. Res. Clin. Rheumatol. 29, 550–565 (2015). - DOI - PubMed
1. Vinson, D. et al. Impact of tapering targeted therapies (bDMARDs or JAKis) on the risk of serious infections and adverse events of special interest in patients with rheumatoid arthritis or spondyloarthritis: a systematic analysis of the literature and meta-analysis. Arthritis Res. Ther. 22, 97 (2020). - DOI - PubMed - PMC